




Goat Anti-Porcine IgG(H+L)

Cat. No.	Format	Size
6050-01	Purified (UNLB)	1.0 mg
6050-02	Fluorescein (FITC)	1.0 mg
6050-04	Alkaline Phosphatase (AP)	1.0 mL
6050-05	Horseradish Peroxidase (HRP)	1.0 mL
6050-08	Biotin (BIOT)	1.0 mg
6050-09	R-phycoerythrin (PE)	0.5 mg
6050-30	Alexa Fluor [®] 488 (AF488)	1.0 mg



FLISA plate was coated with purified porcine IgG. Immunoglobulin was detected with Goat Anti-Porcine IgG(H+L)-AF488 (SB Cat. No. 6050-30).

Description

Specificity	Reacts with the heavy and light chains of porcine IgG
Source	Pooled antisera from goats hyperimmunized with porcine IgG
Cross Adsorption	None; may react with immunoglobulins from other species and the light chains of other porcine immunoglobulins
Purification	Affinity chromatography on porcine IgG covalently linked to agarose

Applications

Quality tested applications include –

ELISA¹⁻¹¹
FLISA

Other referenced applications include –

FC^{1,12}
IHC-PS¹³
ICC¹⁴
WB^{6,7,9,15-24}

Working Dilutions

ELISA	AP conjugate	1:2,000 – 1:4,000
	HRP conjugate	1:4,000 – 1:8,000
	BIOT conjugate	1:5,000 – 1:20,000
FLISA	FITC and AF488 conjugates	1:200 – 1:400
	PE conjugate	≤ 1 µg/mL

Other Applications Since applications vary, you should determine the optimum working dilution for the product that is appropriate for your specific need.

For Research Use Only. Not for Diagnostic or Therapeutic Use.

Corporate Offices: 160 Oxmoor Blvd • Birmingham, AL 35209 • USA Mailing Address: P.O. Box 26221 • Birmingham, AL 35260 • USA

Tel: 205.945.1774 • U.S. and Canada: 800.722.2255 • Fax: 205.945.8768

Email: info@southernbiotech.com • Website: www.southernbiotech.com

Handling and Storage

- The purified (UNLB) antibody is supplied as 1.0 mg purified immunoglobulin in 1.0 mL of borate buffered saline, pH 8.2. *No preservatives or amine-containing buffer salts added.* Store at 2-8°C.
- The fluorescein (FITC) conjugate is supplied as 1.0 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The alkaline phosphatase (AP) conjugate is supplied as 1.0 mL in a stock solution of 50 mM Tris/1 mM MgCl₂/50% glycerol, pH 8.0, containing NaN₃ as preservative. Store at 2-8°C or long-term at -20°C.
- The horseradish peroxidase (HRP) conjugate is supplied as 1.0 mL in a stock solution of 50% glycerol/50% PBS, pH 7.4. No preservative added. Store at 2-8°C or long-term at -20°C.
- The biotin (BIOT) conjugate is supplied as 1.0 mg in 2.0 mL of PBS/NaN₃. Store at 2-8°C.
- The R-phycoerythrin (PE) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN₃ and a stabilizing agent. Store at 2-8°C. **Do not freeze!**
- The Alexa Fluor[®] 488 (AF488) conjugate is supplied as 1.0 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- Protect fluorochrome-conjugated forms from light. Reagents are stable for the period shown on the label if stored as directed.

Warning

Some reagents contain sodium azide. Please refer to product specific SDS.

References

1. Takamatsu H, Andersen JK, Denyer MS, Parkhouse RM. Establishment of long-term CD154-dependent porcine B-cell cultures. *Immunology*. 1999;97:211-8. (ELISA, FC)
2. Hampson DJ, Robertson ID, La T, Oxberry SL, Pethick DW. Influences of diet and vaccination on colonisation of pigs by the intestinal spirochaete *Brachyspira* (Serpulina) pilosicoli. *Vet Microbiol*. 2000;73:75-84. (ELISA)
3. La T, Phillips ND, Reichel MP, Hampson DJ. Protection of pigs from swine dysentery by vaccination with recombinant BmpB, a 29.7 kDa outer-membrane lipoprotein of *Brachyspira hyodysenteriae*. *Vet Microbiol*. 2004;102:97-109. (ELISA)
4. Linghua Z, Xingshan T, Fengzhen Z. The efficacy of CpG oligodinucleotides, in combination with conventional adjuvants, as immunological adjuvants to swine streptococcal septicemia vaccine in piglets in vivo. *Int Immunopharmacol*. 2006;6:1267-76. (ELISA)
5. Linghua Z, Yong G, Xingshan T, Fengzhen Z. CpG oligodinucleotides induce strong humoral and cellular responses to swine streptococcal septicemia vaccine in piglets in vivo. *Int Immunopharmacol*. 2006;6:342-50. (ELISA)
6. Yao Q, Qian P, Huang Q, Cao Y, Chen H. Comparison of immune responses to different foot-and-mouth disease genetically engineered vaccines in guinea pigs. *J Virol Methods*. 2008;147:143-50. (ELISA, WB)
7. Zhou M, Guo Y, Zhao J, Hu Q, Hu Y, Zhang A, et al. Identification and characterization of novel immunogenic outer membrane proteins of *Haemophilus parasuis* serovar 5. *Vaccine*. 2009;27:5271-7. (ELISA, WB)
8. La T, Phillips ND, Hampson DJ. Evaluation of recombinant Bhp29.7 as an ELISA antigen for detecting pig herds with swine dysentery. *Vet Microbiol*. 2009;133:98-104. (ELISA)
9. Li J, Xia J, Tan C, Zhou Y, Wang Y, Zheng C, et al. Evaluation of the immunogenicity and the protective efficacy of a novel identified immunogenic protein, SsPepO, of *Streptococcus suis* serotype 2. *Vaccine*. 2011;29:6514-9. (ELISA, WB)
10. Fu S, Zhang M, Xu J, Ou J, Wang Y, Liu H, et al. Immunogenicity and protective efficacy of recombinant *Haemophilus parasuis* SH0165 putative outer membrane proteins. *Vaccine*. 2013;31:347-53. (ELISA)
11. Hudson LC, Seabolt BS, Odle J, Bost KL, Stahl CH, Piller KJ. Sublethal staphylococcal enterotoxin B challenge model in pigs to evaluate protection following immunization with a soybean-derived vaccine. *Clin Vaccine Immunol*. 2013;20:24-32. (ELISA)
12. Grierson SS, King DP, Tucker AW, Donadeu M, Mellencamp MA, Haverson K, et al. Ontogeny of systemic cellular immunity in the neonatal pig: correlation with the development of post-weaning multisystemic wasting syndrome. *Vet Immunol Immunopathol*. 2007;119:254-68. (FC)
13. Londoño DP, Alvarez JI, Trujillo J, Jaramillo MM, Restrepo BI. The inflammatory cell infiltrates in porcine cysticercosis: immunohistochemical analysis during various stages of infection. *Vet Parasitol*. 2002;109:249-59. (IHC-PS)
14. Tao Q, Fang R, Zhang W, Wang Y, Cheng J, Li Y, et al. Protective immunity induced by a DNA vaccine-encoding *Toxoplasma gondii* microneme protein 11 against acute toxoplasmosis in BALB/c mice. *Parasitol Res*. 2013;112:2871-7. (ICC)
15. Jiang Y, Xiao S, Fang L, Yu X, Song Y, Niu C, et al. DNA vaccines co-expressing GP5 and M proteins of porcine reproductive and respiratory syndrome virus (PRRSV) display enhanced immunogenicity. *Vaccine*. 2006;24:2869-79. (WB)
16. Zhang A, Chen B, Mu X, Li R, Zheng P, Zhao Y, et al. Identification and characterization of a novel protective antigen, Enolase of *Streptococcus suis* serotype 2. *Vaccine*. 2009;27:1348-53. (WB)
17. Liao Y, Deng J, Zhang A, Zhou M, Hu Y, Chen H, et al. Immunoproteomic analysis of outer membrane proteins and extracellular proteins of *Actinobacillus pleuropneumoniae* JL03 serotype 3. *BMC Microbiol*. 2009;9:172. (WB)
18. Zhang A, Chen B, Mu X, Zhao Y, Zheng P, Chen H, et al. Identification of three novel in vivo-induced expressed antigens during infection with *Streptococcus suis* serotype 2. *FEMS Microbiol Lett*. 2009;295:17-22. (WB)
19. Zhang A, Mu X, Chen B, Liu C, Han L, Chen H, et al. Identification and characterization of IgA1 protease from *Streptococcus suis*. *Vet Microbiol*. 2010;140:171-5. (WB)
20. Jeong H, Song Y, Lee S, Lee J, Park S, Song C, et al. Comparative measurement of cell-mediated immune responses of swine to the M and N proteins of porcine reproductive and respiratory syndrome virus. *Clin Vaccine Immunol*. 2010;17:503-12. (WB)
21. Chen X, Liu J. Generation and immunogenicity of transgenic potato expressing the GP5 protein of porcine reproductive and respiratory syndrome virus. *J Virol Methods*. 2011;173:153-8. (WB)
22. Fu Q, Wei Z, Liu X, Xiao P, Lu Z, Chen Y. Glyceraldehyde-3-phosphate dehydrogenase, an immunogenic *Streptococcus equi* ssp. *zoepidemicus* adhesion protein and protective antigen. *J Microbiol Biotechnol*. 2013;23:579-85. (WB)
23. Zhang R, Li C, He W, Wang C, Xu T, Jin M, et al. Development of latex agglutination test with nucleoprotein as antigen for detection of antibodies to swine influenza virus. *Int Immunopharmacol*. 2014;19:201-5. (WB)
24. Lee J, Kwon B, Osorio FA, Pattnaik AK, Lee N, Lee S, et al. Protective humoral immune response induced by an inactivated porcine reproductive and respiratory syndrome virus expressing the hypo-glycosylated glycoprotein 5. *Vaccine*. 2014;32:3617-22. (WB)

Alexa Fluor[®] 488, 647, and 555 are provided under an Intellectual property license from Life Technologies Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. For information on purchasing a license to this product for any other use, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com.

TB6050
09-Dec-19

Corporate Offices: 160 Oxmoor Blvd • Birmingham, AL 35209 • USA Mailing Address: P.O. Box 26221 • Birmingham, AL 35260 • USA

Tel: 205.945.1774 • U.S. and Canada: 800.722.2255 • Fax: 205.945.8768

Email: info@southernbiotech.com • Website: www.southernbiotech.com